ARVN News and Press, Arvinas Inc. From 11/24/25

NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been accepted for presentation at t...

2025-11-24 03:24:22 ET Arvinas: initiating with a hold rating due to limited upside Arvinas ( ARVN ) is a Boston-based biotech founded in 2013, focusing on PROTAC, targeted protein degradation technology, which are bifunctional small molecules that induce ubiquitination and ...

2025-11-05 15:02:10 ET More on Arvinas Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript Arvinas announces $100M share repurchase program Arvinas, Pfizer to out...

2025-11-05 15:01:13 ET Arvinas, Inc. (ARVN) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Jeff Boyle - Vice President of Investor Relations John Houston - Chairperson, CEO & President Noah Berkowitz - Chief Medical Officer Angela...

2025-11-05 07:15:27 ET More on Arvinas Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript Arvinas announces $100M share repurchase program Arvinas, Pfizer to outlicense commercialization of cancer asset vepdegestrant ...

– Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson’s disease – – Presented preclinical data from ARV-806 demonstrating robust and differentiated activity in models of KRAS G12D-mutated cancer &#...

Curaleaf Holdings Inc (CURLF) is expected to report $-0.07 for Q3 2025 Southwest Gas Holdings Inc. (DE) (SWX) is expected to report $0.09 for Q3 2025 Terreno Realty Corporation (TRNO) is expected to report $0.65 for Q3 2025 Bio-Techne Corp (TECH) is expected to report $0.36 for Q1 202...

NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc . (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for PROTAC BCL6 degrader ARV-393, in combination with glofitamab...

Amerigo Resources Ltd (ARREF) is expected to report $0.06 for Q3 2025 Bausch + Lomb Corporation (BLCO) is expected to report $0.16 for Q3 2025 Hayward Holdings Inc. (HAYW) is expected to report $0.11 for Q3 2025 Automatic Data Processing Inc. (ADP) is expected to report $2.44 for Q1 2...

– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, colorectal, and lung cancer – – Data underscore differentiation of ARV-806 from other G12D targeting agents in development...